DK1208847T3 - Farmaceutiske præparater til behandling af transplantatafstödning samt autoimmune eller inflammatoriske tilstande - Google Patents

Farmaceutiske præparater til behandling af transplantatafstödning samt autoimmune eller inflammatoriske tilstande

Info

Publication number: DK1208847T3
Authority: DK; Denmark
Prior art keywords: treatment; autoimmune; pharmaceuticals; well; inflammatory conditions
Prior art date: 1996-07-30

Application number

DK01131018T

Other languages

English (en)

Inventor

Gerhard Zenke

Barbara Haeberlin

Armin Meinzer

Hendrik J Schuurman

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-07-30

Filing date

1997-07-29

Publication date

2007-01-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26309775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1208847(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-07-30 Priority claimed from GBGB9615942.1A external-priority patent/GB9615942D0/en

1997-03-18 Priority claimed from GBGB9705684.0A external-priority patent/GB9705684D0/en

1997-07-29 Application filed by Novartis Ag filed Critical Novartis Ag

2007-01-08 Application granted granted Critical

2007-01-08 Publication of DK1208847T3 publication Critical patent/DK1208847T3/da

Links

206010052779 Transplant rejections Diseases 0.000 title abstract 2
230000001363 autoimmune Effects 0.000 title abstract 2
239000003814 drug Substances 0.000 title 1
230000004968 inflammatory condition Effects 0.000 title 1
HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 abstract 2
108010002350 Interleukin-2 Proteins 0.000 abstract 2
239000003112 inhibitor Substances 0.000 abstract 2
230000035897 transcription Effects 0.000 abstract 2
238000013518 transcription Methods 0.000 abstract 2
208000023275 Autoimmune disease Diseases 0.000 abstract 1
229930105110 Cyclosporin A Natural products 0.000 abstract 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
108010036949 Cyclosporine Proteins 0.000 abstract 1
229960001265 ciclosporin Drugs 0.000 abstract 1
-1 e.g. Chemical compound 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 1
229960002930 sirolimus Drugs 0.000 abstract 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 1
239000011885 synergistic combination Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Graft Or Block Polymers (AREA)
Medicinal Preparation (AREA)

DK01131018T 1996-07-30 1997-07-29 Farmaceutiske præparater til behandling af transplantatafstödning samt autoimmune eller inflammatoriske tilstande DK1208847T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9615942.1A GB9615942D0 (en)	1996-07-30	1996-07-30	Organic compounds
GBGB9705684.0A GB9705684D0 (en)	1997-03-18	1997-03-18	Organic compounds
PCT/EP1997/004123 WO1998004279A1 (en)	1996-07-30	1997-07-29	Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin

Publications (1)

Publication Number	Publication Date
DK1208847T3 true DK1208847T3 (da)	2007-01-08

Family

ID=26309775

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK01131018T DK1208847T3 (da)	1996-07-30	1997-07-29	Farmaceutiske præparater til behandling af transplantatafstödning samt autoimmune eller inflammatoriske tilstande
DK97937526T DK0956034T3 (da)	1996-07-30	1997-07-29	Farmaceutiske præparater til behandling af transplantatafstødning, autoimmune eller inflammatoriske tilstande omfattende cyclosporin A og 40-O-(2-hydroxyethyl)-rapamycin

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK97937526T DK0956034T3 (da)	1996-07-30	1997-07-29	Farmaceutiske præparater til behandling af transplantatafstødning, autoimmune eller inflammatoriske tilstande omfattende cyclosporin A og 40-O-(2-hydroxyethyl)-rapamycin

Country Status (14)

Country	Link
US (2)	US6239124B1 (da)
EP (2)	EP1208847B8 (da)
JP (2)	JP3942641B2 (da)
AT (2)	ATE222502T1 (da)
AU (1)	AU730781B2 (da)
CA (1)	CA2261666C (da)
CY (1)	CY2391B1 (da)
DE (2)	DE69736750T2 (da)
DK (2)	DK1208847T3 (da)
ES (2)	ES2182112T3 (da)
NZ (1)	NZ333657A (da)
PT (2)	PT956034E (da)
SI (1)	SI1208847T1 (da)
WO (1)	WO1998004279A1 (da)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI1033128T2 (sl) *	1993-09-28	2012-02-29	Scherer Gmbh R P	Izdelava mehke Ĺľelatinaste kapsule
US5858401A (en)	1996-01-22	1999-01-12	Sidmak Laboratories, Inc.	Pharmaceutical composition for cyclosporines
EP1208847B8 (en) *	1996-07-30	2007-02-14	Novartis AG	Pharmaceutical compositions for the treatment of transplant rejection, as well as autoimmune or inflammatory conditions
US20030199425A1 (en) *	1997-06-27	2003-10-23	Desai Neil P.	Compositions and methods for treatment of hyperplasia
US6890546B2 (en) *	1998-09-24	2005-05-10	Abbott Laboratories	Medical devices containing rapamycin analogs
US20030129215A1 (en) *	1998-09-24	2003-07-10	T-Ram, Inc.	Medical devices containing rapamycin analogs
GB9825632D0 (en) *	1998-11-23	1999-01-13	Novartis Ag	Organic compounds
GB9826882D0 (en) *	1998-12-07	1999-01-27	Novartis Ag	Organic compounds
US20020006901A1 (en)	1999-02-05	2002-01-17	Aldo T. Iacono	Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
JP2002544167A (ja) *	1999-05-10	2002-12-24	ノバルティスアクチエンゲゼルシャフト	有機化合物
AU2002210768B2 (en) *	2000-11-03	2008-01-10	The University Of Manchester	Selective glucocorticoid receptor agonists
US20020127263A1 (en) *	2001-02-27	2002-09-12	Wenda Carlyle	Peroxisome proliferator-acitvated receptor gamma ligand eluting medical device
US8741378B1 (en)	2001-06-27	2014-06-03	Advanced Cardiovascular Systems, Inc.	Methods of coating an implantable device
US6641611B2 (en) *	2001-11-26	2003-11-04	Swaminathan Jayaraman	Therapeutic coating for an intravascular implant
US20040137066A1 (en) *	2001-11-26	2004-07-15	Swaminathan Jayaraman	Rationally designed therapeutic intravascular implant coating
US20080145402A1 (en) *	2001-09-10	2008-06-19	Abbott Cardiovascular Systems Inc.	Medical Devices Containing Rapamycin Analogs
US20030054042A1 (en) *	2001-09-14	2003-03-20	Elaine Liversidge	Stabilization of chemical compounds using nanoparticulate formulations
JP2005506990A (ja) *	2001-10-19	2005-03-10	アイソテクニカインコーポレーテッド	新規のシクロスポリン類似体のマイクロエマルションプレコンセントレート
CA2464717A1 (en) *	2001-10-25	2003-05-15	Atherogenics, Inc.	Compounds and methods for treating transplant rejection
US7682387B2 (en) *	2002-04-24	2010-03-23	Biosensors International Group, Ltd.	Drug-delivery endovascular stent and method for treating restenosis
US6939376B2 (en) *	2001-11-05	2005-09-06	Sun Biomedical, Ltd.	Drug-delivery endovascular stent and method for treating restenosis
US7109169B2 (en) *	2002-06-28	2006-09-19	Hobai Ion A	Method for treating heart failure by inhibiting the sarcolemmal sodium/calcium exchange
CA2492153C (en)	2002-07-16	2012-05-08	Biotica Technology Limited	Production of polyketide fkbp-ligand analogues
NZ538568A (en) *	2002-09-06	2010-09-30	Abbott Lab	Medical device having hydration inhibitor
DK1539157T3 (da) *	2002-09-18	2013-10-07	Univ Pennsylvania	Fremgangsmåde til hæmning af choroidal neovaskularisering
US8202530B2 (en) *	2002-09-27	2012-06-19	Advanced Cardiovascular Systems, Inc.	Biocompatible coatings for stents
AR043504A1 (es) *	2003-03-17	2005-08-03	Novartis Ag	Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias
US7160867B2 (en) *	2003-05-16	2007-01-09	Isotechnika, Inc.	Rapamycin carbohydrate derivatives
WO2005020993A1 (en) *	2003-08-29	2005-03-10	Lifecycle Pharma A/S	Modified release compositions comprising tacrolimus
CN102144961A (zh)	2003-09-18	2011-08-10	参天制药株式会社	经巩膜递送
US20110104186A1 (en)	2004-06-24	2011-05-05	Nicholas Valiante	Small molecule immunopotentiators and assays for their detection
US8709469B2 (en)	2004-06-30	2014-04-29	Abbott Cardiovascular Systems Inc.	Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
GB0417852D0 (en)	2004-08-11	2004-09-15	Biotica Tech Ltd	Production of polyketides and other natural products
US8021849B2 (en) *	2004-11-05	2011-09-20	Siemens Healthcare Diagnostics Inc.	Methods and kits for the determination of sirolimus in a sample
DK1848431T3 (da)	2005-02-09	2016-04-18	Santen Pharmaceutical Co Ltd	Flydende formuleringer til behandling af sygdomme eller tilstande
US8663639B2 (en)	2005-02-09	2014-03-04	Santen Pharmaceutical Co., Ltd.	Formulations for treating ocular diseases and conditions
MX2007009812A (es) *	2005-02-15	2007-10-23	Wyeth Corp	Formulaciones en tableta de 42-ester de rapamicina con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico oralmente biodisponibles.
US8735394B2 (en)	2005-02-18	2014-05-27	Abraxis Bioscience, Llc	Combinations and modes of administration of therapeutic agents and combination therapy
CN105288630A (zh) *	2005-02-18	2016-02-03	阿布拉科斯生物科学有限公司	治疗剂的组合和给予方式以及联合治疗
WO2006095173A2 (en)	2005-03-11	2006-09-14	Biotica Technology Limited	Medical uses of 39-desmethoxyrapamycin and analogues thereof
GB0504994D0 (en)	2005-03-11	2005-04-20	Biotica Tech Ltd	Novel compounds
EP1871366A2 (en) *	2005-03-21	2008-01-02	Macusight, Inc.	Drug delivery systems for treatment of diseases or conditions
WO2006110802A1 (en) *	2005-04-12	2006-10-19	Elan Pharma International Limited	Nanoparticulate and controlled release compositions comprising cyclosporine
US7189582B2 (en) *	2005-04-27	2007-03-13	Dade Behring Inc.	Compositions and methods for detection of sirolimus
EP1879632A2 (en) *	2005-04-29	2008-01-23	Atrium Medical Corporation	Drug delivery coating for use with a medical device and methods of treating vascular injury
JP2009501801A (ja) *	2005-07-18	2009-01-22	ホライゾンセラピューティクス，インコーポレイテッド	イブプロフェンとファモチジンとを含有する医薬およびその投与
US8067451B2 (en)	2006-07-18	2011-11-29	Horizon Pharma Usa, Inc.	Methods and medicaments for administration of ibuprofen
US20080020040A1 (en) *	2006-07-18	2008-01-24	Horizon Therapeutics, Inc.	Unit dose form for administration of ibuprofen
US20080021078A1 (en) *	2006-07-18	2008-01-24	Horizon Therapeutics, Inc.	Methods and medicaments for administration of ibuprofen
KR20140093764A (ko)	2006-02-09	2014-07-28	산텐 세이야꾸 가부시키가이샤	안정한 제제와 그 제조 및 사용 방법
BRPI0709016A2 (pt)	2006-03-23	2011-06-21	Macusight Inc	formulações e métodos para doenças ou condições relacionadas com a permeabilidade vascular
US8067033B2 (en) *	2007-11-30	2011-11-29	Horizon Pharma Usa, Inc.	Stable compositions of famotidine and ibuprofen
WO2008027963A2 (en) *	2006-08-31	2008-03-06	Horizon Therapeutics, Inc.	Nsaid dose unit formulations with h2-receptor antagonists and methods of use
US8661630B2 (en)	2008-05-21	2014-03-04	Abbott Cardiovascular Systems Inc.	Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer
DE102008060549A1 (de)	2008-12-04	2010-06-10	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
US11304960B2 (en)	2009-01-08	2022-04-19	Chandrashekar Giliyar	Steroidal compositions
EP2552439B1 (en)	2010-03-29	2022-07-20	Abraxis BioScience, LLC	Methods of enhancing drug delivery and effectiveness of therapeutic agents
RU2589513C2 (ru)	2010-03-29	2016-07-10	АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи	Способы лечения онкологических заболеваний
US8685433B2 (en)	2010-03-31	2014-04-01	Abbott Cardiovascular Systems Inc.	Absorbable coating for implantable device
KR20190038684A (ko)	2010-06-04	2019-04-08	아브락시스 바이오사이언스, 엘엘씨	췌장암의 치료 방법
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20180153904A1 (en)	2010-11-30	2018-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20120148675A1 (en)	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
JP5652795B2 (ja) *	2011-01-31	2015-01-14	国立大学法人大阪大学	皮膚疾患を処置するための外用薬およびその製造方法
JP2014516075A (ja)	2011-06-06	2014-07-07	シェブロンフィリップスケミカルカンパニーエルピー	癌治療のためのメタロセン化合物の使用
GB201122305D0 (en)	2011-12-23	2012-02-01	Biotica Tech Ltd	Novel compound
US9220759B2 (en)	2012-02-23	2015-12-29	Abbott Cardiovascular Systems Inc.	Treatment of diabetic patients with a drug eluting stent and adjunctive therapy
US9220584B2 (en)	2012-03-30	2015-12-29	Abbott Cardiovascular Systems Inc.	Treatment of diabetic patients with a stent and locally administered adjunctive therapy
EP2705856A1 (en)	2012-09-07	2014-03-12	Deutsches Zentrum für Neurodegenerative Erkrankungen e.V.	Compounds for the treatment of neurodegenerative disorders
ES2797376T3 (es)	2013-01-24	2020-12-02	Palvella Therapeutics Inc	Composiciones para la administración transdérmica de inhibidores de mTOR
CN110101485B (zh)	2013-09-24	2021-07-06	吉纳生命科学公司	用于细胞植入物的气体处理的系统
US9498485B2 (en)	2014-08-28	2016-11-22	Lipocine Inc.	Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en)	2014-08-28	2017-08-31	Lipocine Inc.	(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016205423A2 (en)	2015-06-15	2016-12-22	Lipocine Inc.	Composition and method for oral delivery of androgen prodrugs
US20180321258A1 (en) *	2015-11-06	2018-11-08	The Trustees Of Columbia University In The City Of New York	Exosomal Protein Profiling for Detection of Cardiac Transplant Rejection
CN110167613B (zh)	2016-11-15	2022-01-11	吉纳生命科学公司	适合用于皮下植入物的经皮气体扩散装置
US20180147215A1 (en)	2016-11-28	2018-05-31	Lipocine Inc.	Oral testosterone undecanoate therapy
EP3565520A4 (en)	2017-01-06	2020-08-19	Palvella Therapeutics, Inc.	ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
WO2018148508A1 (en)	2017-02-10	2018-08-16	Mount Tam Biotechnologies, Inc.	Rapamycin analog
EP3618916A4 (en)	2017-05-04	2021-04-14	Giner Life Sciences, Inc.	ROBUST IMPLANTABLE GAS DISPENSING DEVICE AND PROCEDURES, SYSTEMS AND DEVICES THEREFORE
EP3817743A4 (en)	2018-07-02	2022-07-06	Palvella Therapeutics, Inc.	ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
US12150945B2 (en)	2018-07-20	2024-11-26	Lipocine Inc.	Liver disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4894366A (en)	1984-12-03	1990-01-16	Fujisawa Pharmaceutical Company, Ltd.	Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5100899A (en) *	1989-06-06	1992-03-31	Roy Calne	Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5286730A (en) *	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory disease
US5286731A (en)	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory bowel disease
DE69302945T2 (de)	1992-03-27	1996-10-10	American Home Prod	29-Demethoxyrapamycin zur Induktion der Immunosuppression
GB9221220D0 (en) *	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
GB2278780B (en)	1993-05-27	1998-10-14	Sandoz Ltd	Macrolide formulations
GB9601120D0 (en)	1996-01-19	1996-03-20	Sandoz Ltd	Organic compounds
GB9606452D0 (en)	1996-03-27	1996-06-05	Sandoz Ltd	Organic compounds
EP1208847B8 (en) *	1996-07-30	2007-02-14	Novartis AG	Pharmaceutical compositions for the treatment of transplant rejection, as well as autoimmune or inflammatory conditions
JP2002544167A (ja) *	1999-05-10	2002-12-24	ノバルティスアクチエンゲゼルシャフト	有機化合物

1997
- 1997-07-29 EP EP01131018A patent/EP1208847B8/en not_active Expired - Lifetime
- 1997-07-29 SI SI9730756T patent/SI1208847T1/sl unknown
- 1997-07-29 PT PT97937526T patent/PT956034E/pt unknown
- 1997-07-29 ES ES97937526T patent/ES2182112T3/es not_active Expired - Lifetime
- 1997-07-29 NZ NZ333657A patent/NZ333657A/xx not_active IP Right Cessation
- 1997-07-29 AU AU40124/97A patent/AU730781B2/en not_active Expired
- 1997-07-29 AT AT97937526T patent/ATE222502T1/de active
- 1997-07-29 JP JP50851398A patent/JP3942641B2/ja not_active Expired - Lifetime
- 1997-07-29 ES ES01131018T patent/ES2270948T3/es not_active Expired - Lifetime
- 1997-07-29 DE DE69736750T patent/DE69736750T2/de not_active Expired - Lifetime
- 1997-07-29 CA CA2261666A patent/CA2261666C/en not_active Expired - Lifetime
- 1997-07-29 DK DK01131018T patent/DK1208847T3/da active
- 1997-07-29 DK DK97937526T patent/DK0956034T3/da active
- 1997-07-29 US US09/230,618 patent/US6239124B1/en not_active Expired - Lifetime
- 1997-07-29 EP EP97937526A patent/EP0956034B1/en not_active Expired - Lifetime
- 1997-07-29 AT AT01131018T patent/ATE340586T1/de active
- 1997-07-29 PT PT01131018T patent/PT1208847E/pt unknown
- 1997-07-29 DE DE69714861T patent/DE69714861T2/de not_active Expired - Lifetime
- 1997-07-29 WO PCT/EP1997/004123 patent/WO1998004279A1/en not_active Ceased
2001
- 2001-01-11 US US09/758,301 patent/US6455518B2/en not_active Expired - Lifetime
2003
- 2003-11-28 CY CY0300086A patent/CY2391B1/xx unknown
- 2003-12-08 JP JP2003408898A patent/JP4149905B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
ES2182112T3 (es)	2003-03-01
EP1208847A2 (en)	2002-05-29
HK1023720A1 (en)	2000-09-22
EP1208847B1 (en)	2006-09-27
SI1208847T1 (sl)	2007-06-30
CA2261666C (en)	2010-09-14
JP3942641B2 (ja)	2007-07-11
PT956034E (pt)	2002-12-31
US20010008888A1 (en)	2001-07-19
EP1208847A3 (en)	2002-06-12
DK0956034T3 (da)	2002-12-16
ATE340586T1 (de)	2006-10-15
DE69736750T2 (de)	2007-08-16
US6455518B2 (en)	2002-09-24
CA2261666A1 (en)	1998-02-05
JP2004210767A (ja)	2004-07-29
DE69714861D1 (de)	2002-09-26
AU730781B2 (en)	2001-03-15
JP4149905B2 (ja)	2008-09-17
ATE222502T1 (de)	2002-09-15
JP2000505806A (ja)	2000-05-16
CY2391B1 (en)	2004-09-10
WO1998004279A1 (en)	1998-02-05
DE69736750D1 (de)	2006-11-09
US6239124B1 (en)	2001-05-29
EP1208847B8 (en)	2007-02-14
PT1208847E (pt)	2007-07-24
AU4012497A (en)	1998-02-20
EP0956034B1 (en)	2002-08-21
DE69714861T2 (de)	2003-05-22
EP0956034A1 (en)	1999-11-17
NZ333657A (en)	2000-05-26
ES2270948T3 (es)	2007-04-16

Publication	Publication Date	Title
DK1208847T3 (da)	2007-01-08	Farmaceutiske præparater til behandling af transplantatafstödning samt autoimmune eller inflammatoriske tilstande
DK0401747T3 (da)	2004-03-08	Anvendelse af rapamycin og derivater og prolægemidler deraf til fremstilling af et lægemiddel til hæmning af transplantatafstødning hos pattedyr
MX9101869A (es)	1993-04-01	Ciclosporinas, composicion farmaceutica que las contiene y procedimiento para la produccion de las mismas
DE59409200D1 (de)	2000-04-20	Pharmazeutisches Präparat enthaltend Glucosidase- und/oder Amylasehemmer und einen Lipasehemmer
DK0552031T3 (da)	2002-09-23	Oxepan-isomere af rapamycin, der er anvendelige som immunsuppressive midler
WO1998002441A3 (en)	1998-03-05	Non immunosuppressive antifungal rapalogs
TR199801919T2 (xx)	1999-02-22	Rapamisin t�revlerinin damar hastal�klar� ve yabanc� doku naklinde kullan�m�.
ES2115255T3 (es)	1998-06-16	Derivados de rapamicina con el anillo estabilizado en c-22.
DE69736316D1 (de)	2006-08-24	CDMA Signalübertragung über eine analoge optische Leitung
TR199701567T1 (xx)	1998-04-21	Rapamisin t�revleri.
SI1635830T1 (sl)	2009-02-28	Granulirana farmacevtska oblika rapamicin-estra cci-779
DE69529769D1 (de)	2003-04-03	Kombinationspraeparat, welches cyclosporin a oder fk-506 oder rapamycin und ein xanthinderivat enthaelt
WO2004049907A3 (en)	2005-04-28	Compositions and methods for treating transplants
DK0610744T3 (da)	1999-07-19	Sulfonamidaminomethylenderivater som immunosuppressive stoffer
DK1562571T3 (da)	2011-12-05	Kombination af et diamidderivat og immunsuppressive midler til hæmning af transplantatafstødning
NO305021B1 (no)	1999-03-22	Nye arylmetyltioacylhydroksylaminer, og farmas°ytiske preparater inneholdende dem
WO2001026605A3 (en)	2002-06-27	Immunosuppressive composition containing il-2 inhibitor and an adenosine deaminase inhibitor
NL1007178A1 (nl)	1998-03-31	Inrichting en werkwijze voor het besturen van de volgbalans van een optische schijfspeler.